- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 1, 2022Chambers USA Recognizes Five Robins Kaplan Practice Groups And 17 Lawyers In 2022 Guide
-
June 1, 2022Seasoned Attorney Joins Firm’s Business Litigation Group
-
May 26, 2022Shira Shapiro Named Woman of Promise By The Pearl Society
-
June 3, 202219th Annual Advanced Insurance Law
-
June 9, 2022Building Your Brand: Perspectives and Insights from a Diverse Bar
-
June 10, 2022LGBTQ Legal Services: Transgender Name Change Clinic
-
May 24, 2022Briefly: Seeking Fees and Costs While on Appeal
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
June 2, 2022Sandberg Stepping Down as Meta COO After 14 Years
-
June 1, 2022Markets Revert to Recent Form as Pessimism Takes Hold
-
May 27, 2022Unexpectedly Strong Retail Sales Pull Markets Back from the Brink
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Summer 2017

Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
---|---|---|---|---|---|
Avodart | GlaxoSmithKline | Dutasteride Soft Gelatin Capsules | Marksans | Indicated for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate. | 4/7/2017 |
Nasonex | Merck Sharp Dohme | Mometasone Furoate Monohydrate Nasal Spray | Amneal | Indicated to prevent and treat seasonal and year-round allergy symptoms (such as stuffy/runny nose, itching, and sneezing). | 4/11/2017 |
Lozol | Aventis | Indapamide Tablets | ANI | Indicated for treatment of hypertension and swelling associated with congestive heart failure. | 4/19/2017 |
Prometrium | AbbVie | Progesterone Capsules | Dr. Reddy's | Indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea. | 4/21/2017 |
Vytorin | Merck Sharp & Dohme | Ezetimibe / Simvastatin | Impax | Indicated for the treatment of high cholesterol. | 4/26/2017 |
Vytorin | Merck Sharp & Dohme | Ezetimibe / Simvastatin | Teva | Indicated, along with diet, to lower the level of "bad" cholesterol; increase the level of "good" cholesterol; and lower the level of fat in blood. | 4/26/2017 |
Benicar | Daiichi Sankyo | Olmesartan Medoxomil Tablets | Aurobindo | Indicated for treatment of hypertension. | 5/1/2017 |
Benicar HCT | Daiichi Sankyo | Olmesartan Medoxomil / Hydrochlorothiazide Tablets | Aurobindo | Indicated for treatment of hypertension. | 5/1/2017 |
Glumetza | Valeant | Metformin Hydrochloride ER Tablets | Teva | Indicated, along with diet and exercise, to help control high blood sugar in adults with type 2 diabetes mellitus. | 5/15/2017 |
Clolar | Genzyme | Clofarabine Injection | Fresenius Kabi USA | Indicated for treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regiments. | 5/16/2017 |
Doxil | ALZA | Doxorubicin Hydrochloride Liposome Injection | Dr. Reddy's | Indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy; treatment of AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. | 5/17/2017 |
Edecrin | Aton | Ethacrynic Acid Tablets | West-Ward Pharmaceuticals | Indicated for the treatment of edema when an agent with greater diuretic potential than those commonly employed is required. | 5/17/2017 |
Azor | Daiichi Sankyo | Amlodipine / Olmesartan Medoxomil Tablets | Aurobindo | Indicated for treatment of hypertension. | 5/22/2017 |
Namenda | Forest Labs | Memantine Hydrochloride Tablets | Strides | Indicated for treatment of moderate to severe Alzheimer-type dementia. | 5/24/2017 |
Strattera | Eli Lilly | Atomoxetine Capsules | Aceto | Indicated for treatment of Attention-Deficit Hyperactivity Disorder. | 5/31/2017 |
Motrin IB (OTC) | Johnson and Johnson | Ibuprofen Tablets (marketed under OTC brand Nuprin) | Strides | Indicated for the treatment of pain relief from various conditions such as headache, dental pain, muscle aches, or arthritis. It is also used to reduce fever and to relieve minor aches and pain due to the common cold or flu. | 6/1/2017 |
Azilect | Teva | Rasagiline Tablets | Mylan | Indicated for treatment of Parkinson's disease. | 6/2/2017 |
Reclast | Novartis | Zoledronic Acid Injection | Mylan | Indicated for the treatment of Paget's disease of bone in men and women. | 6/2/2017 |
Angiomax | The Medicines Company | Bivalirudin for Injection | Dr. Reddy's | Indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty. | 6/6/2017 |
Pataday | Novartis | Olopatadine Hydrochloride Ophthalmic Solution 0.2% | Teva | Indicated for treatment of ocular itching associated with allergic conjunctivitis. | 6/9/2017 |
Percocet | Vintage | Oxycodone / Acetaminophen Tablets | Camber | Indicated for treatment of moderate to moderately severe pain. | 6/12/2017 |
Norpramin | U.S. Pharmaceutical Holdings II | Desipramine IR Tablets | Heritage | Indicated for the treatment of depression. | 6/12/2017 |
Pataday | Alcon | Olopatadine Hydrochloride Ophthalmic Solution 0.2% | Sandoz | Indicated for treatment of ocular itching associated with allergic conjunctivitis. | 6/12/2017 |
Zetia | Merck Sharp & Dohme | Ezetimibe Tablets | Teva | Indicated to lower levels of total cholesterol and low-density lipoprotein cholesterol in the blood. | 6/12/2017 |
Zetia | Merck Sharp & Dohme | Ezetimibe Tablets | Amneal | Indicated to lower levels of total cholesterol and low-density lipoprotein cholesterol in the blood. | 6/15/2017 |
Wellbutrin XL Tablets | Valeant | Bupropion Hydrochloride ER Tablets | Lupin | Indicated for the treatment of Major Depressive Disorder and prevention of Seasonal Affective Disorder in adults. | 6/15/2017 |
Acticlate | Aqua Pharmaceuticals | Doxycycline Hyclate IR Tablets | Mayne | Indicated for treatment of a number of infections, including adjunctive therapy in severe acne. | 6/15/2017 |
Hycodan | Endo | Hydrocodone Bitartrate / Homatropine Methylbromide Oral Solution | Perrigo | Indicated for the symptomatic relief of cough in adults and children 6 years of age and older. | 6/19/2017 |
Glucotrol XL | Pfizer | Elipizide ER Tablets | Aceto | Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. | 6/20/2017 |
Micardis | Boehringer Ingelheim | Telmisartan Tablets | Camber | Indicated to treat high blood pressure (hypertension). | 6/21/2017 |
Derma-Smoothe/FS Scalp Oil / Derma-Smoothe/FS Body Oil | Hill Laboratories | Fluocinolone Acetonide Scalp Oil / Fluocinolone Acetonide Topical Oil, 0.01% | Perrigo | Indicated for the topical treatment of atopic dermatitis in adult patients and the topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to four weeks. | 6/21/2017 |
Topicort | Taro | Desoximetasone Cream USP, 0.05% / Desoximetasone Cream USP, 0.25% | Lupin | Indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. | 6/22/2017 |
GENERICally Speaking Summer 2017
Related Professionals
Related Publications
First Quarter
ANDA Litigation Settlements
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
New ANDA Cases
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
Generic Launches
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2022
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
August 2, 2021
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.